TABLE 2.
RASSF2 methylation status in primary prostate tissues
| Patient or sample characteristic |
RASSF2 methylation statusa for histological group |
|||||
|---|---|---|---|---|---|---|
| Prostate cancer |
BPH |
Normal |
||||
| M | U | M | U | M | U | |
| No. (%) in age range (yrs) | ||||||
| 40-49 | 1 (100) | 0 | NA | NA | 0 | 3 |
| 50-59 | 16 (100) | 0 | 0 | 5 | 1 (9) | 10 |
| 60-69 | 47 (94) | 3 | 0 | 11 | 1 (8) | 11 |
| >70 | 14 (93) | 1 | 0 | 18 | 1 (17) | 5 |
| No. (%) with serum total PSA (ng/ml) of: | NA | |||||
| <4 | 10 (91) | 1 | 0 | 20 | ||
| 4.1-8 | 22 (92) | 2 | 0 | 7 | ||
| 8.1-12 | 16 (100) | 0 | 0 | 5 | ||
| >12 | 30 (97) | 1 | 0 | 2 | ||
| No. (%) at pathological stage of: | NA | NA | ||||
| T2a | 4 (100) | 0 | ||||
| T2b | 3 (100) | 0 | ||||
| T2c | 22 (100) | 0 | ||||
| T3a | 25 (100) | 0 | ||||
| T3b | 24 (86) | 4 | ||||
| No. (%) with Gleason sum of: | NA | NA | ||||
| 5 | 4 (100) | 0 | ||||
| 6 | 8 (100) | 0 | ||||
| 7 | 40 (93) | 3 | ||||
| 8 | 11 (92) | 1 | ||||
| 9-10 | 15 (100) | 0 | ||||
a
M, methylated; U, unmethylated. The tissue was considered methylated at the RASSF2 promoter if the PMR value was >10%.